Navigation Links
Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
Date:7/14/2015

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ -- Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of Alzheimer's disease. The study has a total planned enrollment of approximately 480 patients and is the first of two Phase 3 trials of AC-1204, an investigational new drug designed to address the metabolic defect of the brain observed in Alzheimer's patients.

"The NOURISH AD trial is progressing well, and we expect to complete enrollment mid-next year," said Accera's President and CEO, Dr. Charles Stacey. "The repeated failure of pipeline drugs for Alzheimer's disease emphasizes the need to explore new mechanisms in order to identify new options for patients. The NOURISH AD study represents a differentiated approach to tackling this disease."

"Instead of addressing amyloid or tau, AC-1204 addresses the metabolic defects seen in the disease," added Samuel Henderson, Ph.D., Accera's vice president of research and development and the study's director. "The only way we can beat Alzheimer's is by testing new drugs in studies like NOURISH AD. We are grateful for the support of all of the patients, caregivers and investigators who have joined us in the effort to find new treatments."

About the NOURISH AD Phase 3 Clinical Study

NOURISH AD is a 26-week, double-blind, randomized, placebo-controlled, parallel-group study investigating the effects of daily administration of AC-1204 in subjects with mild to moderate Alzheimer's disease, with an optional 26-week open-label extension. Conducted at up to 90 sites, the study is currently enrolling patients with an anticipated total of approximately 480 enrolled. The primary and key secondary endpoints will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and global function as measured by the Alzheimer's Disease Study Cooperative Study – Clinicial Global Impression of Change (ADCS-CGIC) after 26 weeks among non-carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4). The study will also evaluate activities of daily living, resource utilization and quality of life among subjects with mild-to-moderate Alzheimer's.

For more information, visit https://www.AD-trial.com

About Accera

Accera, Inc. is a clinical-stage biotechnology company based in Broomfield, Colorado, developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. From its roots in developing a marketed product, Axona®, Accera has advanced to the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease.

For more information, visit www.accerapharma.com.

Accera Media Contacts:                                                  

Russo Partners LLC 

Todd Davenport, Ph.D.
(212) 845-4235                                                        
todd.davenport@russopartnersllc.com

David Schull                                                             
(212) 845-4271
(858) 717-2310 Mobile                                                                                david.schull@russopartnersllc.com                       


'/>"/>
SOURCE Accera, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Accera Appoints Charles Stacey, M.D., as President and CEO
2. Enrollment in Relmada Therapeutics Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
3. Report: Proteomics Research Market Reaches $1.6 Billion
4. Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion
5. Kalorama: Global Medical Device Market Reaches $360 Billion
6. Transvaginal Mesh Settlement News: Boston Scientific Reaches First TVM Settlement, Says Lawsuitsettlementnews.com
7. Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates
8. Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications
9. Block & Leviton LLP Investigates Hospira, Inc. for Possible Breaches of Fiduciary Duty in Connection with Their Proposed Acquisition by Pfizer Inc.
10. Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
11. MediciGlobals Alzheimers Community Reaches 200,000 likes and more than half a million weekly visitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2018)... ALTAMONTE SPRINGS, Fla. (PRWEB) , ... October 05, ... ... of the nation’s leading innovative specialty pharmacies, announces the donation of $12,000 from ... Carolina and South Carolina by Hurricane Florence. BioPlus serves as a partner for ...
(Date:10/5/2018)... ... 05, 2018 , ... A September 20th article in the Richmond Times-Dispatch reports on ... death was ruled to be the result of a head trauma. As the article points ... new California law legalizing helmetless scooter driving for adults. Los Angeles based personal ...
(Date:10/5/2018)... (PRWEB) , ... October 05, 2018 , ... ... announces the second call for entries for its annual “Imagine Me Beyond What ... awareness and acceptance of body images. The competition incorporates mannequins to help ...
Breaking Medicine Technology:
(Date:10/5/2018)... ... 2018 , ... Shofner Vision Center celebrates 25 ... in middle Tennessee and surrounding areas. Recognized by his peers as one of ... Shofner has performed over 40,000 LASIK procedures and 20,000 ocular surgeries and ...
(Date:10/5/2018)... ... October 05, 2018 , ... ... (CHC) 2018, an annual conference on the latest innovations in health care and ... event Oct. 8-11 throughout downtown Kansas City, Missouri. , "We’re really all about ...
(Date:10/5/2018)... ... 05, 2018 , ... The American Orthopaedic Society for Sports Medicine ( AOSSM ... line with the passage of the Sports Medicine Licensure Clarity Act (H.R.302) which was ... The legislation provides legal protection for traveling team physicians and safeguards injured athletes’ timely ...
(Date:10/5/2018)... ... October 05, 2018 , ... Yisrayl Hawkins, Pastor and ... this week that focuses on Prophecy written thousands of years ago, but written for ... be fulfilled along with the Vatican and other leaders that he says, is taking ...
(Date:10/5/2018)... ... October 05, 2018 , ... ... broadcasting company delivering education to healthcare professionals through an all-digital platform, today ... designed exclusively for rheumatologists. , "This is a unique and easy-to-use ...
Breaking Medicine News(10 mins):